Steve, great news: Today, the paper "Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults" you already reported about was published in the journal Vaccine. When you wrote about it, you expected it will never be peer reviewed. But now it is.
Steve, great news: Today, the paper "Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults" you already reported about was published in the journal Vaccine. When you wrote about it, you expected it will never be peer reviewed. But now it is.
This is another proof that they cause more harm than good.
"In the Moderna trial, the excess risk of serious AESIs (15.1 per 10,000 participants) was higher than the risk reduction for COVID-19 hospitalization relative to the placebo group (6.4 per 10,000 participants). In the Pfizer trial, the excess risk of serious AESIs (10.1 per 10,000) was higher than the risk reduction for COVID-19 hospitalization relative to the placebo group (2.3 per 10,000 participants)."
Steve, great news: Today, the paper "Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults" you already reported about was published in the journal Vaccine. When you wrote about it, you expected it will never be peer reviewed. But now it is.
This is another proof that they cause more harm than good.
"In the Moderna trial, the excess risk of serious AESIs (15.1 per 10,000 participants) was higher than the risk reduction for COVID-19 hospitalization relative to the placebo group (6.4 per 10,000 participants). In the Pfizer trial, the excess risk of serious AESIs (10.1 per 10,000) was higher than the risk reduction for COVID-19 hospitalization relative to the placebo group (2.3 per 10,000 participants)."
thanks. this is great.